Medical and Surgical Advancements in the Management of Cystic Fibrosis Chronic Rhinosinusitis

被引：37
作者：
Tipirneni K.E. [1 ]
Woodworth B.A. [2 ,3 ]
机构：
[1] Department of Surgery, University of Alabama at Birmingham, Birmingham
[2] Department of Otolaryngology, University of Alabama at Birmingham, Birmingham
[3] Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham
来源：
Current Otorhinolaryngology Reports | 2017年 / 5卷 / 1期
基金：
美国国家卫生研究院;
关键词：
CFTR; Chronic sinusitis; Cystic fibrosis; Drug therapy; Endoscopic sinus surgery; Ivacaftor; Modified medial maxillectomy; Sinusitis; Surgical therapy;
D O I：
10.1007/s40136-017-0139-3
中图分类号：
学科分类号：
摘要：
Purpose of Review: The purpose of this review is to provide otolaryngologists with the most up-to-date advancements in both the medical and surgical management of CF-related sinus disease. Recent Findings: Recent studies have supported more aggressive chronic rhinosinusitis (CRS) management, often with a combination of both medical and surgical therapies. Comprehensive treatment strategies have been shown to reduce hospital admissions secondary to pulmonary exacerbations in addition to improving CRS symptoms. Still, current management strategies are lacking in both high-level evidence and standardized guidelines. Summary: The unified airway model describes the bi-directional relationship between the upper and lower airways as a single functional unit and suggests that CRS may play a pivotal role in both the development and progression of lower airway disease. Current strategies for CF CRS focus primarily on amelioration of symptoms with antibiotics, nasal saline and/or topical medicated irrigations, and surgery. However, there are no definitive management guidelines and there remains a persistent need for additional studies. Nevertheless, otolaryngologists have a significant role in the overall management of CF, which requires a multidisciplinary approach and a combination of both surgical and medical interventions for optimal outcomes of airway disease. Here, we present a review of currently available literature and summarize medical and surgical therapies best suited for the management of CF-related sinus disease. © 2017, Springer Science+Business Media New York.
引用
收藏
页码：24 / 34
页数：10
相关论文
共 129 条
  • [1] Grosse S.D., Boyle C.A., Botkin J.R., Et al., Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs, MMWR Recomm Rep, 53, RR-13, pp. 1-36, (2004)
  • [2] Chang E.H., New insights into the pathogenesis of cystic fibrosis sinusitis, Int Forum Allergy Rhinol, 4, 2, pp. 132-137, (2014)
  • [3] Derichs N., Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis, Eur Respir Rev, 22, 127, pp. 58-65, (2013)
  • [4] Liang J., Higgins T., Ishman S.L., Boss E.F., Benke J.R., Lin S.Y., Medical management of chronic rhinosinusitis in cystic fibrosis: a systematic review, Laryngoscope, 124, 6, pp. 1308-1313, (2014)
  • [5] Knowles M., Gatzy J., Boucher R., Relative ion permeability of normal and cystic fibrosis nasal epithelium, J Clin Invest, 71, 5, pp. 1410-1417, (1983)
  • [6] Doull I.J., Recent advances in cystic fibrosis, Arch Dis Child, 85, 1, pp. 62-66, (2001)
  • [7] Hulka G.F., Head and neck manifestations of cystic fibrosis and ciliary dyskinesia, Otolaryngol Clin N Am, 33, 6, pp. 1333-1341, (2000)
  • [8] Mainz J.G., Schien C., Schiller I., Et al., Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial, J Cyst Fibros, 13, 4, pp. 461-470, (2014)
  • [9] Tos M., Distribution of mucus producing elements in the respiratory tract. Differences between upper and lower airway, Eur J Respir Dis Suppl, 128, pp. 269-279, (1983)
  • [10] Wine J.J., King V.V., Lewiston N.J., Method for rapid evaluation of topically applied agents to cystic fibrosis airways, Am J Phys, 261, 2, pp. L218-L221, (1991)
12345678910